Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2022

Genmab — Januar 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #61

    Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,200 at Bernstein https://www.avanza.se/placera/telegram/2022/01/04/genmab-bernstein-hojer-riktkursen-for-genmab-till-3-200-danska-kronor-3-150-upprepar-outperform-bn.html

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #62

      Novo og sundhedsaktier ramt af genåbningshåb vurderer strateg https://www.proinvestor.com/investornyt/758638/novo-og-sundhedsaktier-ramt-af-genabningshab-vurderer-strateg

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #63

        Genmab and Synaffix Enter into License Agreement for ADC Technology
        Media Release

        Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
        Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
        Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales

        1 Reply Last reply
        0
        • B Offline
          B Offline
          BioShare
          wrote on sidst redigeret af
          #64

          Genmab og Synaffix indgår aftale om ADC.

          1 Reply Last reply
          0
          • B Offline
            B Offline
            BioShare
            wrote on sidst redigeret af
            #65

            https://ir.genmab.com/news-releases/news-release-details/genmab-and-synaffix-enter-license-agreement-adc-technology

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #66

              Genmab and Synaffix Enter into License Agreement for ADC Technology https://www.proinvestor.com/investornyt/758658/genmab-and-synaffix-enter-into-license-agreement-for-adc-technology

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #67

                site specific conjugation bl.a.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #68

                  bl.a. ?

                  1 Reply Last reply
                  0
                  • M Offline
                    M Offline
                    Mcjean
                    wrote on sidst redigeret af
                    #69

                    onder andere

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #70

                      😉 ok

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #71

                        it isn't that long ago that Jan told us how impressed he was with AbbVie ADC technology, calling it ADC 3.0 ... things change fast i guess

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #72

                          Synaffix even partnered with ADCT ...

                          https://synaffix.com/

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #73

                            https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies

                            1 Reply Last reply
                            0
                            • troldmandenT Offline
                              troldmandenT Offline
                              troldmanden
                              wrote on sidst redigeret af
                              #74

                              Det er ikke helt klart om de $415 mio er per target/antistof, eller om det er den øvre grænse for max x projekter

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                BioShare
                                wrote on sidst redigeret af
                                #75

                                Det er "total potential deal value" + "tired mid-single digits royalty".

                                1 Reply Last reply
                                0
                                • troldmandenT Offline
                                  troldmandenT Offline
                                  troldmanden
                                  wrote on sidst redigeret af
                                  #76

                                  ja men vi ved ikke hvor mange targetes der er tale om. Men egentligt kunne man (læs mig selv) også sige sig selv at der er tale om flere aftaler til det beløb. For der bliver ikke indgået SÅ store deals på enkelt target/antistof der først nu skal startes op. Altså bliver det ikke mere earlystage end det her

                                  1 Reply Last reply
                                  0
                                  • troldmandenT Offline
                                    troldmandenT Offline
                                    troldmanden
                                    wrote on sidst redigeret af
                                    #77

                                    Så vi taler nok 3-5 targets i alt

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #78

                                      Genmab indgår lincensaftale med Synaffix om ADC-teknologi - NY https://www.proinvestor.com/investornyt/758686/genmab-indgar-lincensaftale-med-synaffix-om-adc-teknologi-ny

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #79

                                        trold tænker nok mere 2-3 targets, men igen lidt svært at vurdere ud fra en lidt kringlet tekst

                                        1 Reply Last reply
                                        0
                                        • troldmandenT Offline
                                          troldmandenT Offline
                                          troldmanden
                                          wrote on sidst redigeret af
                                          #80

                                          Sukker jeg tror det er flere targets. De betaler ikke plus $200 mio for en forsknings aftale. Det var sådan en aftale JnJ betale $20 mio per target på den gamle aftale

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper